Together, our findings suggest that clinically available PDE4 inhibitors could be repurposed for CHCHD10<sup>S59L</sup>-linked ALS-FTD, while emphasizing the need to carefully consider the effects of the PINK1/Parkin pathway, as it is generally recognized as a protective pathway. Here, PDE4A is linked to frontotemporal dementia.